MedTrace Logo

Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients

NCT00436592 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2009-02-05

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and feasibility of the NeuroFlo™ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment. The NeuroFlo device is intended to increase blood flow to the brain and potentially reduce the damage caused by stroke.

Conditions

  • Cerebrovascular Accident

Interventions

DEVICE

NeuroFlo™ Catheter

45 minute Treatment

Sponsors & Collaborators

  • CoAxia

    lead INDUSTRY

Principal Investigators

  • Flo 24 Steering Committee · Multiple Organizations

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States
  • Canada
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436592 on ClinicalTrials.gov